FGFR3-TACC3 fusion
|
GBM
|
FGFR3-TACC3 fusion
|
GBM
|
anlotinib Sensitive: C3 – Early Trials
|
anlotinib Sensitive: C3 – Early Trials
|
FGFR3-TACC3 fusion
|
Gallbladder Cancer
|
FGFR3-TACC3 fusion
|
Gallbladder Cancer
|
Debio 1347 Sensitive: C3 – Early Trials
|
Debio 1347 Sensitive: C3 – Early Trials
|
FGFR3-TACC3 fusion
|
Urothelial Cancer
|
FGFR3-TACC3 fusion
|
Urothelial Cancer
|
infigratinib Sensitive: C3 – Early Trials
|
infigratinib Sensitive: C3 – Early Trials
|
FGFR3-TACC3 fusion
|
Urothelial Cancer
|
FGFR3-TACC3 fusion
|
Urothelial Cancer
|
Debio 1347 Sensitive: C3 – Early Trials
|
Debio 1347 Sensitive: C3 – Early Trials
|
FGFR3-TACC3 fusion
|
GBM
|
FGFR3-TACC3 fusion
|
GBM
|
erdafitinib Sensitive: C3 – Early Trials
|
erdafitinib Sensitive: C3 – Early Trials
|
FGFR3-TACC3 fusion
|
NSCLC
|
FGFR3-TACC3 fusion
|
NSCLC
|
infigratinib Sensitive: C3 – Early Trials
|
infigratinib Sensitive: C3 – Early Trials
|
FGFR3-TACC3 fusion
|
NSCLC
|
FGFR3-TACC3 fusion
|
NSCLC
|
ponatinib Sensitive: C3 – Early Trials
|
ponatinib Sensitive: C3 – Early Trials
|
FGFR3-TACC3 fusion
|
Gastric Cancer
|
FGFR3-TACC3 fusion
|
Gastric Cancer
|
TAS 120 Sensitive: C3 – Early Trials
|
TAS 120 Sensitive: C3 – Early Trials
|
FGFR3-TACC3 fusion
|
Glioma
|
FGFR3-TACC3 fusion
|
Glioma
|
anlotinib Sensitive: C4 – Case Studies
|
anlotinib Sensitive: C4 – Case Studies
|
FGFR3-TACC3 fusion
|
Adrenal Cortex Carcinoma
|
FGFR3-TACC3 fusion
|
Adrenal Cortex Carcinoma
|
erdafitinib Sensitive: C4 – Case Studies
|
erdafitinib Sensitive: C4 – Case Studies
|
FGFR3-TACC3 fusion
|
Astrocytoma
|
FGFR3-TACC3 fusion
|
Astrocytoma
|
ABSK091 Sensitive: C4 – Case Studies
|
ABSK091 Sensitive: C4 – Case Studies
|
FGFR3-TACC3 fusion
|
Endometrial Cancer
|
FGFR3-TACC3 fusion
|
Endometrial Cancer
|
erdafitinib Sensitive: C4 – Case Studies
|
erdafitinib Sensitive: C4 – Case Studies
|
FGFR3-TACC3 fusion
|
Bladder Cancer
|
FGFR3-TACC3 fusion
|
Bladder Cancer
|
erdafitinib Sensitive: C4 – Case Studies
|
erdafitinib Sensitive: C4 – Case Studies
|
FGFR3-TACC3 fusion
|
Urothelial Cancer
|
FGFR3-TACC3 fusion
|
Urothelial Cancer
|
atezolizumab Sensitive: C4 – Case Studies
|
atezolizumab Sensitive: C4 – Case Studies
|
FGFR3-TACC3 fusion
|
Bladder Cancer
|
FGFR3-TACC3 fusion
|
Bladder Cancer
|
TAS 120 Sensitive: D – Preclinical
|
TAS 120 Sensitive: D – Preclinical
|
FGFR3-TACC3 fusion
|
Urothelial Cancer
|
FGFR3-TACC3 fusion
|
Urothelial Cancer
|
erdafitinib Sensitive: D – Preclinical
|
erdafitinib Sensitive: D – Preclinical
|
FGFR3-TACC3 fusion
|
Bladder Cancer
|
FGFR3-TACC3 fusion
|
Bladder Cancer
|
MPT0L145 Sensitive: D – Preclinical
|
MPT0L145 Sensitive: D – Preclinical
|
FGFR3-TACC3 fusion
|
Cholangiocarcinoma
|
FGFR3-TACC3 fusion
|
Cholangiocarcinoma
|
infigratinib Sensitive: D – Preclinical
|
infigratinib Sensitive: D – Preclinical
|
FGFR3-TACC3 fusion
|
Urothelial Cancer
|
FGFR3-TACC3 fusion
|
Urothelial Cancer
|
dasatinib + infigratinib Sensitive: D – Preclinical
|
dasatinib + infigratinib Sensitive: D – Preclinical
|